rtki cpd and Angiogenesis, Pathologic

rtki cpd has been researched along with Angiogenesis, Pathologic in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, L; Chen, X; Huang, H; Huang, Z; Li, Y; Ye, X; Yu, N1
Chen, H; Ju, X; Song, Z; Wang, Y; Wu, W; Yan, T; Yang, X; Zhang, Z1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X1

Other Studies

3 other study(ies) available for rtki cpd and Angiogenesis, Pathologic

ArticleYear
PAR2 promotes tumor-associated angiogenesis in lung adenocarcinoma through activating EGFR pathway.
    Tissue & cell, 2022, Volume: 79

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Neovascularization, Pathologic; Receptor, PAR-2; Vascular Endothelial Growth Factor A

2022
EGFR inhibitor, AG1478, inhibits inflammatory infiltration and angiogenesis in mice with diabetic retinopathy.
    Clinical and experimental pharmacology & physiology, 2019, Volume: 46, Issue:1

    Topics: Animals; Diabetic Retinopathy; Disease Progression; ErbB Receptors; Female; Inflammation; Macrophages; Male; Mice; Mitochondria; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Retinal Vessels; Tyrphostins

2019
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17

    Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins

2004